On November 9, 2020 Incyte (Nasdaq:INCY) reported that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, held virtually from November 11-14, 2020 (Press release, Incyte, NOV 9, 2020, View Source [SID1234570311]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to join the oncology community at the SITC (Free SITC Whitepaper) 35th anniversary annual meeting and look forward to sharing data from our immuno-oncology portfolio," said Lance Leopold, Group Vice President, Immuno-Oncology, Incyte. "In particular, initial translational data from the ongoing clinical trial support further development of our orally administered PD-L1 inhibitor INCB86550 — a novel small-molecule discovered at Incyte."
E-Poster Presentations:
Pharmacodynamic Biomarkers Demonstrate T-Cell Activation in Patients Treated with the Oral PD-L1 Inhibitor INCB086550 in a Phase 1 Clinical Trial [Poster #419]
Retrospective Pooled Analysis of Epacadostat Clinical Studies Identifies Doses Required for Maximal Pharmacodynamic Effect in Anti-PD-1 Combination Studies [Poster #28]
MCLA-145 (CD137xPD-L1): A Potent CD137 Agonist and Immune Checkpoint Inhibitor That Does Not Show Signs of Peripheral Toxicity [Poster #814] 1
MCLA-145 is a Bispecific IgG1 Antibody that Inhibits PD-1/PD-L1 Signaling While Simultaneously Activating CD137 Signaling on T Cells [Poster #820]1
A Phase 1 Study of Retifanlimab (INCMGA00012), a PD-1 Inhibitor, in Patients with Advanced Solid Tumors: Preliminary Results in Recurrent MSI-High or dMMR Endometrial Cancer (POD1UM-101) [Poster #268]
A Phase 2 Umbrella Study of Retifanlimab (INCMGA00012) Alone or in Combination with Other Therapies in Patients with Advanced or Metastatic Endometrial Cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO) [Trial in Progress; Poster #348]2
All posters will be on display from Monday, November 9, 2020 until the virtual poster hall closes on December 31, 2020.
Abstracts are available on the SITC (Free SITC Whitepaper) 2020 website at View Source